Literature DB >> 12833016

Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis.

Antonella Tosti1, Bianca Maria Piraccini, Massimiliano Pazzaglia, Colombina Vincenzi.   

Abstract

BACKGROUND: Efficacy of topical steroids in alopecia areata is still discussed.
OBJECTIVE: The purpose of this study was to evaluate the efficacy of clobetasol propionate 0.05% ointment under occlusion in 28 patients with alopecia areata totalis (AT) or AT/alopecia universalis.
METHODS: A total of 28 patients were instructed to apply 2.5 g of clobetasol propionate to the right side of the scalp every night under occlusion with a plastic film. Treatment was performed 6 days a week for 6 months. When regrowth of terminal hair occurred, treatment was extended over the entire scalp. All patients were followed up for another 6 months.
RESULTS: Of the 28 patients included in the study, 8 were treated successfully (28.5%). Regrowth of terminal hair began on the treated side 6 to 14 weeks after the start of treatment. Of these 8 patients, 3 had a relapse and were not able to maintain hair regrowth.
CONCLUSION: Our study shows that clobetasol propionate 0.05% under occlusion is effective in inducing hair regrowth in patients with AT or AT/alopecia universalis. Occurrence of hair regrowth only on the treated half of the scalp clearly shows that efficacy of treatment is a result of a local and not systemic effect of the drug. Although only 17.8% of patients had long-term benefit by treatment, our results were obtained in a population of patients with severe and refractory forms of the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12833016     DOI: 10.1067/mjd.2003.423

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  17 in total

Review 1.  Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.

Authors:  Ralph M Trüeb; Maria Fernanda Reis Gavazzoni Dias
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  A randomized comparative study of the efficacy of topical latanoprost versus topical betamethasone diproprionate lotion in the treatment of localized alopecia areata.

Authors:  Sonali Bhat; Sanjeev Handa; Dipankar De
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Jan-Feb       Impact factor: 2.545

3.  Annular alopecia areata: report of two cases.

Authors:  Manish Bansal; Kajal Manchanda; Ss Pandey
Journal:  Int J Trichology       Date:  2013-04

Review 4.  Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.

Authors:  A Sterkens; J Lambert; A Bervoets
Journal:  Clin Exp Med       Date:  2021-01-01       Impact factor: 3.984

Review 5.  Alopecia areata: Part 2: treatment.

Authors:  Frank Spano; Jeff C Donovan
Journal:  Can Fam Physician       Date:  2015-09       Impact factor: 3.275

6.  Treatment of Severe Alopecia Areata: Combination Therapy Using Systemic Cyclosporine A with Low Dose Corticosteroids.

Authors:  Deborah Lee; Doo Jin Oh; Jung Wook Kim; Sung Wook Park; Min Kyung Oh; Ho Suk Sung; Seon Wook Hwang
Journal:  Ann Dermatol       Date:  2008-12-31       Impact factor: 1.444

Review 7.  Alopecia Areata: An Update on Treatment Options for Children.

Authors:  Lauren Peloquin; Leslie Castelo-Soccio
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

Review 8.  Alopecia areata.

Authors:  C Herbert Pratt; Lloyd E King; Andrew G Messenger; Angela M Christiano; John P Sundberg
Journal:  Nat Rev Dis Primers       Date:  2017-03-16       Impact factor: 52.329

9.  A Retrospective Study on Alopecia Areata in Children: Clinical Characteristics and Treatment Choices.

Authors:  Christina Stefanaki; George Kontochristopoulos; Eleni Hatzidimitraki; Aravella Stergiopoulou; Alexandra Katsarou; Vasiliki Vosynioti; Eleni Remountaki; Dimitrios Rigopoulos
Journal:  Skin Appendage Disord       Date:  2021-09-14

Review 10.  New and Emerging Therapies for Alopecia Areata.

Authors:  Aunna Pourang; Natasha Atanaskova Mesinkovska
Journal:  Drugs       Date:  2020-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.